MapLight Therapeutics has announced an oversubscribed $372.5 million Series D financing.   The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors, including Sanofi, accounts advised by T Rowe Price Investment Management, Inc. and Avego BioScience Capital.   The financing also included strong participation from MapLight’s existing investors, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!